Novavax CEO to Visit SK Bioscience Andong Plant Today

Discussion Scheduled on Raw Material Supply and Permit Progress Status

[Image source=Yonhap News]

[Asia Economy Reporter Kim Ji-hee] Stanley Erck, CEO of Novavax, will visit SK Bioscience's Andong plant, which is in charge of contract manufacturing of the COVID-19 vaccine.

According to SK Bioscience on the 26th, CEO Erck will visit the Andong plant in Gyeongbuk, where Novavax vaccine technology is being introduced and produced, during his visit to Korea. An SK Bioscience official stated, "Novavax's management and working-level staff will visit the Andong plant, which is conducting licensing and contract development and manufacturing (CDMO), to discuss the supply of raw materials and progress of approvals for smooth production."

Through this visit, CEO Erck plans to tour the production facilities of the Andong plant and check the progress of approvals. However, specific schedules have not been disclosed.

During his visit to Korea, CEO Erck is also expected to meet with officials from the government-wide Vaccine Introduction Task Force (TF). It is anticipated that discussions to accelerate domestic approval procedures may take place at this meeting.

The Novavax COVID-19 vaccine scheduled to be introduced in Korea amounts to a total of 20 million doses (40 million shots). All of these are produced domestically by SK Bioscience. Earlier in January, President Moon Jae-in personally discussed the domestic supply and technology transfer of the Novavax vaccine with CEO Erck via a video conference.

This content was produced with the assistance of AI translation services.